Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Single-Agent Zactima/ZD6474 in Advanced NSCLC
Author
Howard (Jack) West, MD

As introduced in the last post, ZD6474, or Zactima, is a pill that blocks tumor blood supply and at higher doses (in the 300 mg per day range) also blocks EGFR. This mutli-targeted therapy has shown some intriguing activity when combined with chemo, and today I'll focus on the research that gave it as a single agent and where it has led us in terms of current trials.

As I mentioned in my previous post, an early phase I trial just trying to establish an optimal dose showed some activity zactima as a single-agent, as 4 of 9 patients with NSCLC in a Japanese trial showed significant tumor shrinkage on zactima. From there, Dr. Ron Natale at Cedars-Sinai Medical Center in Los Angeles led a randomized phase II trial (abstract here) that compared zactima as a single agent at the higher dose of 300 mg by mouth per day, pretty close to the maximal feasible dose, to iressa at 250 mg by mouth daily. The trial was designed to allow cross-over to the other drug after patients experienced either progression or problematic side effects. So the design was as shown here:

Zactima vs Iressa Natale schema revised (click to enlarge)

There were a total of 168 patients, previously treated with one or two prior lines of therapy, and patients with treated brain metastases were allowed to enroll. They found that the time to disease progression was about 30% longer in the people who received zactima compared with the iressa recipients, 11 vs. 8 weeks. The response rates were modest for both groups but higher for zactima (8%) than iressa (1%, which is pretty disappointing, frankly). From the "waterfall plot", you can see that there are clearly more people with some degree of tumor shrinkage on zactima than on iressa. A waterfall plot shows the overall change in tumor volume from all measured tumors on a scan, and bars going upward above the horizonal line indicate overall growth, while bars going downward indicate overall shrikage. So the closer the "waterfall" is to the left, the more shrinkage vs. progression there was on a certain treatment. Here's the plot ffor zactima vs. iressa in the first part of the trial (before cross-over):

Zactima vs. Iressa waterfall plots

After progression or side effect problems, patients could cross over to the other drug. However, many patients declined rapidly or otherwise didn't continue on the trial, so only 29 patients went on to iressa after zactima, of whom there was a single response and a stable disease rate of 24%. Of the 37 patients who received zactima after iressa, there were no objective responses, but the stable disease/disease control rate was 43%.

The overall survival was not significantly different between the two groups. This is not especially surprising, since both groups had the potential to receive the benefits of each drug. However, it was a bit surprising to see that the trend in survival was actually in favor of the folks who received Iressa first, then switched to Zactima, given that the rest of the activity measures favored the early Zactima recipients, and fewer than half of the patients on the Iressa first arm received Zactima at all. The survival curves are shown here:

Zactima vs Iressa overall survival curves

Lastly, there's the issue of side effects. Basically, they were pretty similar, with rash seen in about half, diarrhea seen more commonly with zactima, about a third of patients with nausea, and about 20% of patients on zactima developing asymptomatic EKG changes (changes in the electrical system of the heart). This last one is certainly something that AstraZeneca, the company that makes zactima, is following closely, and we need to take seriously, but fortunately we really haven't seen serious cardiac complications on zactima to this point. Other side effects were pretty infrequent. For a drug that has anti-angiogenic activity, we really haven't seen serious bleeding complications on zactima.

At the end of the day, what can we say about this trial? It has a lot of promising leads, such as the improvement in progression-free survival on zactima compared with iressa. Too bad iressa didn't beat placebo on a clinical trial, so that's not as exciting as being superior to a more active drug. And then there's the issue of the survival actually being a bit better (numerically, not statistically) in the folks who received iressa first and then went on zactima. Finally, none of the results was remarkable, with all of the response rates in single digits and the survival numbers OK, but not inspiring.

So there are no conclusions to take to the bank, but Zactima warrants further study. AstraZeneca has started a larger phase III randomized trial comparing Zactima to Tarceva, which has been shown to improve survival in the previously treated advanced NSCLC setting, unlike Iressa. This trial (AZ Trial 57 info here) is just getting started, and another one for patients who have already received Iressa or Tarceva is testing Zactima vs. a placebo (AZ Trial 44 info here). We'll get a good sense of what this drug has to offer from these larger trials that are just getting started.

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on